No Carolina / NY / Florida
Ph: 561.316.3330

Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes Market

Both Nordic and international investors were attracted by Sigrid's natural, non-drug alternative SiPore® technology

Summation

  • “Sigrid’s continued success is evident from the launch of one of the world’s largest prediabetes trial, SHINE, to SiPore21®’s medical device classification and the commercial traction in our oral health vertical.
  • We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,”.
  • The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health.

Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid’s innovative SiPore® technology.

The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health. SiPore21®, the company’s flagship product, is currently undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21® utilises a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.

“This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,” says Sana Alajmovic, Co-Founder and CEO of Sigrid Therapeutics.

“Sigrid’s continued success is evident from the launch of one of the world’s largest prediabetes trial, SHINE, to SiPore21®’s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential,” adds Mattias Ankarberg, Sigrid’s Chairman.

“We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions,” adds Lars Molinder, financial adviser to Sigrid Therapeutics.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Enifer Secures €36M In Funding

Enifer, a biotech scaleup is gearing up the production of its PEKILO® mycoprotein with a new €33M factory located in Kirkkonummi, Finland. With already existing collaborations with the world’s leading food and feed companies, Enifer is prepared to annually upcycle food industry side streams into up to 3,000 tons of its sustainable fungi-based protein

Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Funding will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations reports Phenomix Sciences.

R3 Vascular Announces $87 Million in Series B Financing

R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy